Tesamorelin is a stabilized GHRH analog and the only GHRH-analog peptide to reach FDA approval (as Egrifta) — studied specifically for deep abdominal (visceral) fat.
In a randomized human trial, daily tesamorelin reduced visceral adipose tissue by 18% over 52 weeks and lowered triglycerides, without clinically significant changes in glucose[1].
It acts on the pituitary GHRH receptor to restore GH/IGF-1 signaling; visceral fat re-accumulates once treatment stops, underlining that the effect is treatment-dependent.
Supplied as a lyophilized powder for reconstitution. Figures above summarize published clinical research on this molecule and are provided as scientific reference for laboratory research only.
Couldn't load pickup availability
Need reconstitution solution? Don’t forget to add Bacteriostatic Water — available as a quick add in your cart before checkout.
GHRH Analog
The Only FDA-Approved GHRH Analog: 4× More Effective Than Alternatives
Tesamorelin is a 44-amino-acid synthetic GHRH analog with a trans-3-hexanoic acid modification that increases plasma stability and half-life. It preserves physiological pulsatile GH secretion while delivering clinically validated results — reducing visceral adiposity by nearly 20% and proving approximately 4× more effective than all other available therapies combined. This makes tesamorelin the gold standard for metabolic and body composition research.
- 44-amino-acid GHRH analog with enhanced stability
- Trans-3-hexanoic acid modification extends half-life
- Preserves physiological pulsatile GH release
- ~20% reduction in visceral adiposity
- 4× more effective than combined alternative therapies
Metabolic & Cardiovascular Research
How Tesamorelin Targets Visceral Fat and Cardiovascular Risk
Tesamorelin stimulates the pituitary to release GH in natural pulses, which then drives IGF-1 production and metabolic optimization. Research demonstrates significant reductions in triglycerides, total cholesterol, and non-HDL-C — a 15% reduction in visceral adipose tissue correlates with a 50 mg/dL decrease in triglycerides. By reducing ectopic fat deposition, tesamorelin directly decreases the inflammation that drives cardiovascular disease risk.
- Stimulates pulsatile GH release via GHRH receptor
- Increases IGF-1 levels physiologically
- Reduces triglycerides, total cholesterol, non-HDL-C
- 15% visceral fat reduction = 50 mg/dL triglyceride drop
- Decreases ectopic fat-driven inflammation
Expanding Research Applications
From Nerve Regeneration to Cognitive Protection
Beyond metabolic research, tesamorelin shows promise in peripheral nerve regeneration and mild cognitive impairment (MCI). A randomized, double-blind trial at the University of Washington demonstrated that tesamorelin improves executive function and verbal memory in MCI patients — potentially by increasing brain GABA levels and decreasing myo-inositol. Its existing regulatory pathway makes it an attractive candidate for clinical translation.
- Peripheral nerve regeneration studies
- Mild cognitive impairment (MCI) research
- Increases brain GABA levels
- Improves executive function and verbal memory
- Established regulatory pathway (FDA-approved status)
The Science Behind GHRH Signaling: Why Tesamorelin Leads Metabolic Research
Tesamorelin represents the pinnacle of GHRH analog development. As a 44-amino-acid synthetic peptide with a trans-3-hexanoic acid modification, it achieves enhanced plasma stability while preserving the physiological pulsatile pattern of GH release. This is a critical distinction from exogenous GH administration, which obliterates natural secretory rhythms and causes more side effects.
The clinical data is compelling. In lipodystrophy research, tesamorelin reduced visceral adiposity by nearly 20% — approximately 4× more effective than all other available interventions combined. Beyond fat reduction, it improved the entire metabolic profile: triglycerides dropped in direct correlation with visceral fat loss (15% fat reduction = 50 mg/dL triglyceride decrease), and total cholesterol and non-HDL-C levels improved significantly.
The cardiovascular implications are profound. Ectopic fat deposition — visceral, hepatic, and epicardial — drives chronic inflammation that underlies cardiovascular disease. By specifically targeting this dysfunctional fat accumulation, tesamorelin addresses root causes rather than symptoms. This makes it particularly valuable for research into metabolic syndrome, insulin resistance, and age-related body composition changes.
Emerging research extends beyond metabolism. A 20-week randomized controlled trial demonstrated that tesamorelin improves executive function and verbal memory in patients with mild cognitive impairment — potentially by increasing brain GABA levels and decreasing myo-inositol. Peripheral nerve regeneration studies show similar promise. For research teams investigating GH physiology, metabolic dysfunction, neuroprotection, or cardiovascular risk, tesamorelin provides a clinically validated, physiologically appropriate tool with an established regulatory pathway.
For research use only. Not for human consumption.
Packaged with care, shipped fast.
The Qovigen Difference
Tesamorelin – 10 mg — Qovigen vs. a typical supplier.
Qovigen
Tesamorelin – 10 mg
Qovigen Peptides
Competitor
Tesamorelin – 10 mg
Typical Competitor
01 /
Higher Purity
02 /
Better Price
03 /
Faster Shipping
04 /
Verified Quality
After testing more than $8,500 worth of vials over the past year, Qovigen ranks first — set apart by genuinely new production technology.
Dr Aimen Arij
Doctor of Pharmacology · Lead Writer, dosagepeptide.com